LIMN
Live News • 16h
Liminatus Pharma Revises InnocsAI Merger to Expand Oncology Cell Therapy Pipeline Liminatus Pharma amended its definitive merger agreement with InnocsAI to broaden its oncology cell therapy pipeline, with the transaction expected to close on 2 July 2026, subject to customary closing conditions.
The company describes the InnocsAI merger as a transformational step that widens its development portfolio and creates multiple potential avenues for long-term shareholder value in oncology cell therapy.
Liminatus Pharma shares trade at around $0.11, with the stock down 82.8% year to date, which frames the merger as a high-impact corporate event against a weak recent trading backdrop.
This deal shifts the story around Liminatus Pharma toward pipeline scale and optionality in oncology cell therapy, but it also concentrates execution risk around integrating InnocsAI and advancing a larger set of programs with limited market confidence currently reflected in the share price. Announcement • May 28
Liminatus Pharma, Inc. Receives Notice of Delisting Due to Non-Compliance with Nasdaq Listing Standards As previously disclosed in the Current Report on Form 8-K filed on November 25, 2025 with the Securities and Exchange Commission, on November 19, 2025, Liminatus Pharma, Inc. received notices from The Nasdaq Stock Market LLC (Nasdaq), indicating that the Company's listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Rule) and the $15,000,000 market value of publicly held shares (MVPHS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(C) (the MVPHS Rule). The Company was provided a period of 180 calendar days, or until May 18, 2026, in which to regain compliance. On May 20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will be delisted from The Nasdaq Global Market. Unless the Company requests an appeal of the determination before the Nasdaq Hearings Panel (the Panel) by May 27, 2026, trading of the Company's common stock will be suspended at the opening of business on May 29, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on Nasdaq. On May 26, 2026, the Company requested an appeal before the Panel. The hearing request will result in a stay of any suspension or delisting action pending the hearing. Board Change • May 20
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. CEO & Chairman Chris Kim is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
